Other languages Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Delayed Nasdaq Other stock markets 12:15:21 2024-06-11 pm EDT			5-day change	1st Jan Change
3.92 ^USD	-1.01%		+10.11%	-8.20%

May. 31	Prelude Therapeutics Files for $400 Million Mixed Shelf	MT
May. 07	Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Prelude Therapeutics Files for $400 Million Mixed Shelf	May. 31
Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	Apr. 10
Prelude Therapeutics Shares Surge Following Shelf Registration	Feb. 16
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference	23-10-14
Prelude Therapeutics Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Insider Buy: Prelude Therapeutics	23-05-24
Debt Ceiling Deal Hopes Boost Exchange-Traded Funds, Equity Futures Pre-Bell Thursday	23-05-18
Prelude Therapeutics Launches $100 Million Public Offering	23-05-17
Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08
Prelude Therapeutics Forms Hematologic Cancer Clinical Trial Partnership with BeiGene	23-03-15
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15
Prelude Therapeutics Incorporated Announces Clinical Trial Collaboration with BeiGene	23-03-15
Prelude Therapeutics Falls on BofA Downgrade	22-11-21
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter Ended September 30, 2022	22-11-14
Prelude Therapeutics to Proceed With Phase 1 Study of PRT3789 Product Candidate	22-10-18
Prelude Therapeutics Incorporated Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader	22-10-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Other languages

Filters